SCHEMBL12947966

SCHEMBL12947966

COc1cc(OC)c2nc(C)c3c(C)nc(CI)n3c2c1

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 20/20 0.57
PDE2A O00408 19/20 0.57
PDE11A Q9HCR9 5/20 0.57
PDE5A O76074 4/20 0.57
PDE4A P27815 3/20 0.57
PDE6D O43924 2/20 0.43
PDE6A P16499 2/20 0.43
PDE6G P18545 2/20 0.43
PDE6B P35913 2/20 0.43
PDE6C P51160 2/20 0.43
PDE6H Q13956 2/20 0.43
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41
ADORA2A P29274 1/20 0.41
ADORA1 P30542 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL970666 0.87 PDE10A (0.55) PDE10APDE2APDE11APDE5APDE4A
SCHEMBL12947964 0.87 PDE2A (0.58) PDE10APDE2APDE11APDE5APDE4A
SCHEMBL12948061 0.85 PDE10A (0.60) PDE10APDE2APDE11APDE5APDE4A
SCHEMBL969355 0.76 PDE10A (0.67) PDE10APDE2APDE11APDE5APDE4A
SCHEMBL970391 0.74 PDE10A (0.77) PDE10APDE2APDE11APDE5APDE4A
SCHEMBL969353 0.74 PDE10A (0.52) PDE10APDE2APDE11APDE5APDE4A
SCHEMBL972494 0.73 PDE10A (0.72) PDE10APDE2APDE11APDE5APDE4A
SCHEMBL971800 0.73 PDE10A (1.00) PDE10APDE2APDE11APDE5APDE4A
SCHEMBL972290 0.72 PDE2A (1.00) PDE10APDE2APDE11APDE5APDE4A
SCHEMBL968670 0.72 PDE10A (1.00) PDE10APDE2APDE11APDE5APDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7875618-B2 8-chloro-3,4-dimethyl-1-(2- methylphenyl)imidazo[1,5- a]quinoxaline; inhibitors of phosphodiesterase 10; for treatment of central nervous system disorders (cognitive deficits, social phobia, reduced vigilance, obesity and psychosis) WYETH (US) 2011-01-25 US disclosed